Lv65
1790 积分 2022-11-21 加入
Advances in systemic therapies for triple negative breast cancer
9分钟前
已完结
Olaparib and durvalumab in patients with germline BRCA-mutated metastatic breast cancer (MEDIOLA): an open-label, multicentre, phase 1/2, basket study
1小时前
已完结
Sacituzumab Govitecan in Untreated, Advanced Triple-Negative Breast Cancer
10天前
已完结
Sustained benefit of adjuvant olaparib in women with germline BRCA1- and BRCA2- -associated high-risk HER2-negative early breast cancer: Updated results from the OlympiA phase III trial
13天前
已关闭
The next generation of antibody-drug conjugates
14天前
已完结
Antibody-drug conjugate design and mechanisms of action for cancer treatment: state of the art and beyond
14天前
已完结
Synergistic strategies: ADC-PARP inhibitor combinations in triple-negative breast cancer therapy
15天前
已完结
The Pathologic Response Evaluation and Detection in Circulating Tumor-DNA Study: Ultrasensitive Circulating Tumor-DNA Assessment of Breast Cancer Minimal Residual Disease
15天前
已完结
Circulating tumor DNA in breast cancer: From technological foundation to clinical implementation
15天前
已完结
Circulating Tumor DNA in Early Breast Cancer: A Review
15天前
已完结
皖公网安备34019202002308
